Biotech Startups

Eos BioInnovation invests in early-stage regenerative medicine therapies and technologies, focusing on cell, gene, and tissue therapies that target disease causes. The firm partners with researchers and entrepreneurs to accelerate the translation of breakthrough science into commercial biotech companies.

1 investor

1 investor

Epiaxis Therapeutics develops treatments for advanced cancers.

1 investor

1 investor

Epicyt Pharma is a pharmaceutical R&D company developing treatments focused on intestinal calcium absorption and its effect on bone health, with its lead candidate BAFA aimed at restoring calcium uptake and preventing osteoporosis. The company is based in Gothenburg, Sweden.

1 investor

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for chronic respiratory diseases such as COPD, based on research into macrolides and their effects on the lung epithelium. Its lead program, EP395 (glasmacinal), is a non-antibacterial macrolide with anti-inflammatory activity that is Phase 2b ready.

1 investor

Epimune develops and commercializes epigenetics-based molecular diagnostic tests that quantify immune cells from a drop of blood, aimed at diagnosing and monitoring patients with immune system disorders. Its methods support home blood sampling and dried-blood spot analysis, such as quantifying B cells in patients on anti-CD20 therapies.

1 investor

Episteme is an in-house R&D organization that hires researchers across disciplines and provides funding, infrastructure, and operational support to pursue translational science aimed at real-world impact. It models itself on research environments such as Bell Labs, the Institute for Advanced Study, and Xerox PARC.

1 investor

Epitome Therapeutics is an early-stage biotechnology company developing CADENCE, an epigenome editing platform that controls gene expression without changing the DNA sequence. It targets diseases driven by dysregulated gene activity, including rare and metabolic disorders.

1 investor

Epivara is developing an injectable, permanent alternative to surgical spay and neuter procedures for mammals, intended to be administered in a single shot without anesthesia or incisions. Its products (iSpay, iNeuter, and iNeuter-S) target pets such as cats and dogs, small animals, and livestock in the meat industry to control reproduction and reduce hormone-related issues like boar taint.

1 investor

EpiVax works with biologic and vaccine developers to assess and manage immunogenicity risk across the product lifecycle, combining in silico analysis with in vitro testing to produce actionable immunogenicity data. The company helps pharmaceutical and vaccine partners reduce risk and build regulatory-ready strategies for safer therapies.

1 investor

An integrated discovery platform for rapidly identifying high-quality VHH lead molecules from humanized libraries using cDNA display technology and developability assessment for drug research programs.

1 investor

EPTAM provides precision machining, plastics, and molding manufacturing services for regulated industries including medical and aerospace sectors. The company operates multiple facilities offering quality assurance and automated inspection capabilities.

1 investor

Eptiva Therapeutics develops a precision medicine approach to pain treatment, using a bioinformatic network biology platform connected to a proprietary pain landscape database that links drug targets and biological pathways to pain-related diseases. Its Personalized Analgesics platform aims to de-risk pain drug R&D and improve clinical success rates.

1 investor

eQcell develops regenerative medicine therapies for veterinary use, aiming to treat animal conditions that are poorly addressed by current treatments. The company focuses on novel cell-based therapies to improve animal welfare.

1 investor

Equigerminal provides DNA testing services for equine genetic conditions, specifically polysaccharide storage myopathy type 1 (PSSM1) in horses. The company operates a laboratory in Portugal offering genetic analysis through mail-in samples.

1 investor

1 investor

Equulus Therapeutics is a biotech company developing psychedelic-inspired small-molecule therapeutics for central nervous system and psychiatric disorders, including suicidality in depression, substance use disorder, PTSD, obesity, and seizure disorders. It uses a serotonin releaser technology platform to design compounds intended to retain therapeutic effects while reducing cardiotoxicity, hallucinatory, and abuse-related liabilities.

1 investor

ErebaGen activates silent microbial biosynthetic pathways to discover new biocatalysts and enzymes, enabling greener and more cost-effective routes to industrial chemicals. It works with partners in pharma, biotech, and chemical manufacturing to replace hazardous chemical steps and develop sustainable manufacturing routes.

1 investor

Eris Biotech develops small-molecule drugs designed to block immune suppression mechanisms, allowing the immune system to attack solid tumors; the company is initially focusing on mesothelioma treatments.

1 investor

Esco Aster provides independent technical and investor due diligence services across biotechnology, pharmaceuticals, medical technology, and related life sciences sectors. The company advises venture capital funds, family offices, universities, and other stakeholders on scientific validity, intellectual property, manufacturing, regulatory compliance, and commercial feasibility of life science investments and technologies.

1 investor

Esco Lifesciences manufactures laboratory equipment, biopharma devices, and IVF medical equipment for clinical, research, and industrial laboratories across more than 100 countries. The company operates multiple business units including Esco Scientific for laboratory equipment, Esco Medical for ART/IVF solutions, Esco Healthcare for pharma and biotech support, and Esco Aster as a CDMO offering continuous manufacturing platforms.

1 investor

1 investor

Eshelman Innovation supports the development of healthcare therapeutics and digital health ideas from academic research toward real-world application. It focuses on catalyzing innovation aimed at major healthcare challenges.

1 investor